GB202404021D0 - Cell-based neurotoxin assay - Google Patents
Cell-based neurotoxin assayInfo
- Publication number
- GB202404021D0 GB202404021D0 GBGB2404021.4A GB202404021A GB202404021D0 GB 202404021 D0 GB202404021 D0 GB 202404021D0 GB 202404021 A GB202404021 A GB 202404021A GB 202404021 D0 GB202404021 D0 GB 202404021D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell
- assay
- neurotoxin assay
- based neurotoxin
- neurotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710138657 Neurotoxin Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2404021.4A GB202404021D0 (en) | 2024-03-20 | 2024-03-20 | Cell-based neurotoxin assay |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2404021.4A GB202404021D0 (en) | 2024-03-20 | 2024-03-20 | Cell-based neurotoxin assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202404021D0 true GB202404021D0 (en) | 2024-05-01 |
Family
ID=90826200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2404021.4A Pending GB202404021D0 (en) | 2024-03-20 | 2024-03-20 | Cell-based neurotoxin assay |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202404021D0 (en) |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992006204A1 (en) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Surface expression libraries of heteromeric receptors |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO2006027207A1 (en) | 2004-09-06 | 2006-03-16 | Toxogen Gmbh | Transport protein which is used to introduce chemical compounds into nerve cells |
| WO2006114308A2 (en) | 2005-04-26 | 2006-11-02 | Toxogen Gmbh | Carrier for targeting nerve cells |
| US20070166332A1 (en) | 2005-09-19 | 2007-07-19 | Allergan, Inc. | Clostridial Toxin Activatable Clostridial Toxins |
| WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US8071110B2 (en) | 1999-08-25 | 2011-12-06 | Allergan, Inc. | Activatable clostridial toxins |
| EP2635582A1 (en) | 2010-11-02 | 2013-09-11 | Promega Corporation | Novel coelenterazine substrates and methods of use |
| US8557970B2 (en) | 2009-05-01 | 2013-10-15 | Promega Corporation | Synthetic Oplophorus luciferases with enhanced light output |
| WO2013180799A1 (en) | 2012-05-30 | 2013-12-05 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| EP2677029A2 (en) | 2011-05-19 | 2013-12-25 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2014080206A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2015004461A1 (en) | 2013-07-09 | 2015-01-15 | Syntaxin Limited | Cationic neurotoxins |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| WO2016154534A1 (en) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| WO2017191315A1 (en) | 2016-05-05 | 2017-11-09 | Ipsen Biopharm Limited | Chimeric neurotoxins |
| WO2018009903A2 (en) | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| WO2018075783A2 (en) | 2016-10-20 | 2018-04-26 | President And Fellows Of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| WO2020065336A1 (en) | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Clostridial neurotoxins comprising an exogenous activation loop |
-
2024
- 2024-03-20 GB GBGB2404021.4A patent/GB202404021D0/en active Pending
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1992006204A1 (en) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Surface expression libraries of heteromeric receptors |
| US8071110B2 (en) | 1999-08-25 | 2011-12-06 | Allergan, Inc. | Activatable clostridial toxins |
| WO2006027207A1 (en) | 2004-09-06 | 2006-03-16 | Toxogen Gmbh | Transport protein which is used to introduce chemical compounds into nerve cells |
| WO2006114308A2 (en) | 2005-04-26 | 2006-11-02 | Toxogen Gmbh | Carrier for targeting nerve cells |
| US20070166332A1 (en) | 2005-09-19 | 2007-07-19 | Allergan, Inc. | Clostridial Toxin Activatable Clostridial Toxins |
| WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US8557970B2 (en) | 2009-05-01 | 2013-10-15 | Promega Corporation | Synthetic Oplophorus luciferases with enhanced light output |
| EP2635582A1 (en) | 2010-11-02 | 2013-09-11 | Promega Corporation | Novel coelenterazine substrates and methods of use |
| EP2677029A2 (en) | 2011-05-19 | 2013-12-25 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2013180799A1 (en) | 2012-05-30 | 2013-12-05 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| WO2014080206A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2015004461A1 (en) | 2013-07-09 | 2015-01-15 | Syntaxin Limited | Cationic neurotoxins |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| WO2016154534A1 (en) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| WO2017191315A1 (en) | 2016-05-05 | 2017-11-09 | Ipsen Biopharm Limited | Chimeric neurotoxins |
| WO2018009903A2 (en) | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| WO2018075783A2 (en) | 2016-10-20 | 2018-04-26 | President And Fellows Of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| WO2020065336A1 (en) | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Clostridial neurotoxins comprising an exogenous activation loop |
Non-Patent Citations (47)
| Title |
|---|
| "NCBI", Database accession no. NP_112253 .1 |
| "UniProt", Database accession no. P04958 |
| ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 - 16 |
| BENSON, MARC A. ET AL.: "Unique ganglioside recognition strategies for clostridial neurotoxins.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 39, 2011, pages 34015 - 34022, XP055485185, DOI: 10.1074/jbc.M111.272054 |
| BOTTENSTEINSATO, PNAS, vol. 76, 1979, pages 514 - 517 |
| BOWIESAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 6 |
| BREWERCOTMAN, BRAIN RES., vol. 494, 1989, pages 65 - 74 |
| C. E. LAWRENCE ET AL.: "Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment", SCIENCE, vol. 262, no. 5131, 1993, pages 208 - 214, XP001152872, DOI: 10.1126/science.8211139 |
| CHEN ET AL., J. NEUROSCI. METHODS, vol. 171, no. 2, 2008, pages 239 - 247 |
| CHUNG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10145 - 9 |
| CHUNG ET AL., SCIENCE, vol. 259, 1993, pages 806 - 9 |
| CRAIG ET AL., BIOCHEM J, vol. 276, 1991, pages 637 - 641 |
| CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 5 |
| DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 12 |
| DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145 |
| ELLMAN ET AL., METHODS ENZYMOL., vol. 202, 1991, pages 301 |
| ERIC DEPIEREUXERNEST FEYTMANS: "Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences", CABIOS, vol. 8, no. 5, 1992, pages 501 - 509 |
| HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991, HARPER PERENNIAL |
| HALPERN J, J. BIOL. CHEM., vol. 268, no. 15, 1993, pages 11188 - 11192 |
| HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 19 |
| HERREROS J, BIOCHEM. J., vol. 347, 2000, pages 199 - 204 |
| HONG ET AL., JOURNAL OF BIOMOLECULAR SCREENING, vol. 21, no. 1, 2016, pages 65 - 73 |
| HONG ET AL., TOXICOLOGICAL SCIENCES, vol. 134, no. 1, 2013, pages 64 - 72 |
| IVO VAN WALLE ET AL.: "Align-M -A New Algorithm for Multiple Alignment of Highly Divergent Sequences", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1428 - 1435 |
| JULIE D. THOMPSON ET AL.: "CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix Choice", NUCLEIC ACIDS RESEARCH, vol. 22, no. 22, 1994, pages 4673 - 4680, XP002956304 |
| KNAPP, AM. CRYST. ASSOC. ABSTRACT PAPERS, vol. 25, 1998, pages 90 |
| KOIDE ET AL., BIOCHEM., vol. 33, 1994, pages 7470 - 6 |
| KROKEN, ABBY R. ET AL.: "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 30, 2011, pages 26828 - 26837, XP055190569, DOI: 10.1074/jbc.M111.254086 |
| LACEY DB, NAT. STRUCT. BIOL., vol. 5, 1998, pages 898 - 902 |
| LAM, KWOK-HO ET AL.: "Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin", PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY, vol. 117, no. 2, 2015, pages 225 - 231, XP029586798, DOI: 10.1016/j.pbiomolbio.2015.02.004 |
| LEDEEN, ROBERT W.GUSHENG WU.: "The multi-tasked life of GM1 ganglioside, a true factotum of nature.", TRENDS IN BIOCHEMICAL SCIENCES, vol. 40, no. 7, 2015, pages 407 - 418, XP002768079, DOI: 10.1016/j.tibs.2015.04.005 |
| LOWMAN ET AL., BIOCHEM., vol. 30, 1991, pages 10832 - 7 |
| NER ET AL., DNA, vol. 7, 1988, pages 127 |
| OSAMU GOTOH: "Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments", J. MOL. BIOL., vol. 264, no. 4, 1996, pages 823 - 838 |
| REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 53 - 7 |
| ROBERTSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 2722 |
| RUMMEL A, MOL. MICROBIOL., vol. 51, no. 3, 2004, pages 631 - 643 |
| RUMMEL A, PNAS, vol. 104, 2007, pages 359 - 364 |
| SESARDIC ET AL., BIOLOGICALS, vol. 31, no. 4, 2003, pages 265 - 276 |
| SESARDIC ET AL., PHARMACOL TOXICOL, vol. 78, no. 5, 1996, pages 283 - 8 |
| SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS |
| SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904 |
| SWAMINATHANESWARAMOORTHY, NAT. STRUCT. BIOL., vol. 7, 2000, pages 1751 - 1759 |
| TURCATTI ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 19991 - 8 |
| UMLAND TC, NAT. STRUCT. BIOL., vol. 4, 1997, pages 788 - 792 |
| WLODAVER ET AL., FEBS LETT., vol. 309, 1992, pages 59 - 64 |
| WYNNRICHARDS, PROTEIN SCI., vol. 2, 1993, pages 395 - 403 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006018288D1 (en) | ELASTOMER STRUCTURES | |
| GB202404021D0 (en) | Cell-based neurotoxin assay | |
| SG11202102111SA (en) | Cell-based clostridal neurotoxin assays | |
| KR102613646B9 (en) | Novel bacillus velezensis with antivacterial activity for antibiotics resistant enterobacteia | |
| GB202404192D0 (en) | Pro-c12 assay | |
| GB202404073D0 (en) | Bigh3m-n assay | |
| GB202309589D0 (en) | Microfluidic enzyme assays | |
| WO2004043991A3 (en) | Assay for tissue factor and factor viia | |
| EP3995586A4 (en) | Glycosylated protein assay reagent containing protease stabilizer increasing redox potential of ferrocyanide, method for assaying glycosylated protein, method for preserving glycosylated protein assay reagent, and method for stabilizing glycosylated protein assay reagent | |
| GB202016699D0 (en) | Antibody assay | |
| GB202301141D0 (en) | Pro-c5 assay | |
| GB202215897D0 (en) | Neostatin-14 assay | |
| GB202410791D0 (en) | Protein expression reagents | |
| GB202407052D0 (en) | Protein expression reagents | |
| GB202404122D0 (en) | Viral biomarker assay | |
| GB202213479D0 (en) | Cell-free clostridial neurotoxin assays | |
| GB202311804D0 (en) | Enzyme | |
| GB202408178D0 (en) | assays on expressed proteins | |
| GB202315935D0 (en) | Novel enzymes | |
| GB202218069D0 (en) | Enzymes | |
| GB202213127D0 (en) | Antibody assay | |
| GB202209866D0 (en) | Cross linked collagen type v assay | |
| GB202312548D0 (en) | Protein expression reagents | |
| GB202311184D0 (en) | Protein expression reagents | |
| GB202213114D0 (en) | Microfluidic cell |